Valeant Pharmaceuticals International Inc stock trades on the US exchange.

Trading Profile: Valeant Pharmaceuticals International, a specialty pharmaceutical company, engages in the development, manufacture, and marketing of a range of pharmaceutical products. It primarily offers prescription pharmaceutical products in the areas of neurology, dermatology, and infectious diseases. The company’s neurology products include Diastat and Diastat AcuDial, Mestinon, Cesamet, Librax, Dalmane/Dalmadorm, Migranal, Tasmar, Melleril, and Zelapar. Its dermatology products comprise Efudex/Efudix, Kinerase, Oxsoralen-Ultra, and Dermatix. The company also offers various infectious disease products, such as Virazole, the brand name for ribavirin; and other therapeutic products, including Bedoyecta, ...

»»» Detailed Company Profile & Chart

 Valeant Pharmaceuticals International Inc current day financials: 2024-04-25 11:44:33am
Symbol Name Purchase price Last Price Change % Change
0.00
Valeant Pharmaceuticals International Inc historical financials from '16
Open
28.91
Day Range
28.71 - 29.39
Volume
15,449,178
Previous Close
29.03
52Wk Range
18.55 - 245.82
1 Yr Return
-87.00%
YTD Return
-71.35%
Current P/E Ratio (TTM)
-
Earnings per Share (USD) (TTM)
-0.45
Market Cap (b USD)
9.935
Shares Outstanding (m)
341.191
Price/Sales (TTM)
0.97
Dividend Indicated Gross Yield
-
Sector
Health Care
Industry
Biotech & Pharma
Sub-Industry
Specialty Pharma

Recent VRX News from Yahoo Finance & Seeking Alpha

Older Archived News Valeant Pharmaceuticals International Inc

  • FedEx Soars, Ackman Sells Mondelez (FDX, MDLZ).
  • Valeant (VRX) Stock Plunges as Creditors Renegotiate Agreements.
  • March 17 Premarket Briefing: 10 Things You Should Know.
  • Stocks Inch Higher as Fed Countdown Begins.
  • VALEANT PHARMACEUTICALS INTL (VRX) Earnings Report: Q4 2015 Conference Call Transcript.
  • Valeant Analyst: More Bad News to Come.
  • Bloomberg Advantage: Koon on Investors Frustration with Valeant.
  • Stocks Slide as Oil Trades at Lowest Level in a Week.
  • Markets Cautious Ahead of Tomorrow's Fed Meeting (VRX, DSW).
  • Valeant (VRX) Stock Plunges on Q4 Results, Jim Cramer: 'I Have No Idea What the Earnings Power Is'.
    • Load More News...